News | May 03, 2025
SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification
This significant milestone enhances our global regulatory standing
This significant milestone enhances our global regulatory standing
The FDA issued Form 483 with one observation related to building and facility management
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The Subsidiary has received one inspectional observation in Form 483
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Subscribe To Our Newsletter & Stay Updated
